167 related articles for article (PubMed ID: 36499455)
1. Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects.
Zhang S; Liu Y; Zhou J; Wang J; Jin G; Wang X
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499455
[TBL] [Abstract][Full Text] [Related]
2. Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.
Zhou SH; Li YT; Zhang RY; Liu YL; You ZW; Bian MM; Wen Y; Wang J; Du JJ; Guo J
Front Immunol; 2022; 13():857779. PubMed ID: 35371101
[TBL] [Abstract][Full Text] [Related]
3. Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects.
Liu Y; Tang L; Gao N; Diao Y; Zhong J; Deng Y; Wang Z; Jin G; Wang X
Oncol Lett; 2020 Sep; 20(3):2369-2377. PubMed ID: 32782554
[TBL] [Abstract][Full Text] [Related]
4. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
[TBL] [Abstract][Full Text] [Related]
5. CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity.
Jie J; Zhang Y; Zhou H; Zhai X; Zhang N; Yuan H; Ni W; Tai G
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558459
[TBL] [Abstract][Full Text] [Related]
6. New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses.
Gutjahr A; Papagno L; Vernejoul F; Lioux T; Jospin F; Chanut B; Perouzel E; Rochereau N; Appay V; Verrier B; Paul S
EBioMedicine; 2020 Aug; 58():102922. PubMed ID: 32739871
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
[TBL] [Abstract][Full Text] [Related]
8. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
Front Immunol; 2022; 13():936129. PubMed ID: 36059502
[TBL] [Abstract][Full Text] [Related]
9. Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and α-Mannose as Adjuvants.
Shinchi H; Yamaguchi T; Moroishi T; Yuki M; Wakao M; Cottam HB; Hayashi T; Carson DA; Suda Y
Bioconjug Chem; 2019 Nov; 30(11):2811-2821. PubMed ID: 31560198
[TBL] [Abstract][Full Text] [Related]
10. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
12. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
13. A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist.
Chi H; Hao Y; Wang X; Tang L; Deng Y; Chen X; Gao F; Sha O; Jin G
Cells; 2022 Jun; 11(13):. PubMed ID: 35805071
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
Glaffig M; Stergiou N; Schmitt E; Kunz H
ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
[TBL] [Abstract][Full Text] [Related]
16. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
[TBL] [Abstract][Full Text] [Related]
17. An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo.
Zhu H; Wang K; Wang Z; Wang D; Yin X; Liu Y; Yu F; Zhao W
Acta Biomater; 2022 Jan; 138():491-504. PubMed ID: 34757230
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M
Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model.
Gao FS; Zhan YT; Wang XD; Zhang C
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):353-357. PubMed ID: 30111221
[TBL] [Abstract][Full Text] [Related]
20. Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays.
Inglefield J; Catania J; Harris A; Hickey T; Ma Z; Minang J; Baranji K; Spangler T; Look J; Ruiz C; Lu H; Alleva D; Reece JJ; Lacy MJ
Vaccine; 2022 Sep; 40(38):5544-5555. PubMed ID: 35773119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
